Novartis and Eli Lilly sign separate $1.9bn novel drug deals

Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

FDA targets faster generic approvals in drive to slash drug prices

27 August 2026 Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.

Regulation & Industry

The buyers' wishlist: What makes a life sciences deal stack up?

25 August 2026 While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.

Regulation & Industry

UK appoints ex-engineer as new intellectual property Minister

24 August 2026 Labour MP for Stockton North takes up a new role as Minister for Science, Innovation and Investment within Andy Burnham’s government.